Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-07-08

FDA Approved: ELREXFIO — Supplemental Application (U.S. Pharmaceuticals)

View source ↗

Summary

The FDA approved a supplemental application for ELREXFIO (elranatamab-BCMM) filed by U.S. Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ELREXFIO (ELRANATAMAB-BCMM)

Snippet

SUPPL AP for ELREXFIO (ELRANATAMAB-BCMM)